Modified Ectodomain of Human EGFR as a Potential Anticancer Agent

Case ID:

Development of a protein that attenuates EGFR and/or EGFR family members and is comprised of a modified EGFR ectodomain. The protein inhibits signaling via the EGFR and/or EGFR family members. The protein includes a portion of the EGFR (or EGFR family member) and the "U" region epitope of EGFR related protein (ERRP), wherein the portion of the EGFR is operable to bind a ligand of EGFR.  Attenuating EGFR signaling can include inhibiting the EGFR and/or EGFR family members and to provide antiproliferative activity. The present proteins and expression of nucleic acids encoding these proteins can regulate cellular growth and can be used to treat tumors and cancerous cells that express one or more of the EGFR and EGFR family members.  Preclinical data suggests that this protein works against difficult to treat triple negative breast cancer (TNBC) as well as other types of cancers.

Patents: PCT

Patent Information:
For Information, Contact:
Frank Urban
Commercialization Principal
Wayne State University
Adhip Majumdar
Arun Rishi
Yingjie Yu
Breast Cancer
Cancer Therapies
Drug Target